Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,214,186
  • Shares Outstanding, K 127,830
  • Annual Sales, $ 1,004 M
  • Annual Income, $ 22,390 K
  • EBIT $ 55 M
  • EBITDA $ 59 M
  • 60-Month Beta -0.19
  • Price/Sales 5.18
  • Price/Cash Flow 194.70
  • Price/Book 13.91

Options Overview Details

View History
  • Implied Volatility 20.81% (-1.53%)
  • Historical Volatility 248.10%
  • IV Percentile 3%
  • IV Rank 14.43%
  • IV High 97.27% on 07/28/25
  • IV Low 7.92% on 04/07/26
  • Expected Move (DTE 6) 0.29 (0.71%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 4,459
  • Volume Avg (30-Day) 2,723
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 51,517
  • Open Int (30-Day) 30,809
  • Expected Range 40.50 to 41.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.38
  • Number of Estimates 12
  • High Estimate $-0.17
  • Low Estimate $-0.62
  • Prior Year $-0.74
  • Growth Rate Est. (year over year) +48.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.83 +142.36%
on 03/30/26
40.79 unch
on 04/10/26
+21.15 (+107.69%)
since 03/10/26
3-Month
16.83 +142.36%
on 03/30/26
40.79 unch
on 04/10/26
+13.49 (+49.41%)
since 01/09/26
52-Week
16.10 +153.35%
on 05/15/25
40.79 unch
on 04/10/26
+22.00 (+117.08%)
since 04/10/25

Most Recent Stories

More News
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KZR : 7.37 (+0.27%)
CNTA : 39.48 (-0.70%)
APLS : 40.79 (+0.34%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS

NEW YORK , April 8, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of...

AFBI : 22.31 (unch)
KZR : 7.37 (+0.27%)
CNTA : 39.48 (-0.70%)
APLS : 40.79 (+0.34%)
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KORE : 9.15 (-0.11%)
CNTA : 39.48 (-0.70%)
APLS : 40.79 (+0.34%)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

NEW YORK , April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

APLS : 40.79 (+0.34%)
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals...

APLS : 40.79 (+0.34%)
BIIB : 172.97 (-2.34%)
Stocks Surge on Signs the US and Iran Seek to End War

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +2.91%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +2.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.43%. June E-mini...

ALK : 39.50 (-1.00%)
GOOGL : 317.24 (-0.39%)
AAPL : 260.48 (unch)
SNDK : 851.77 (+0.02%)
ADI : 350.14 (-0.35%)
CNTA : 39.48 (-0.70%)
OXY : 57.97 (-0.96%)
TSLA : 348.95 (+0.96%)
STX : 503.13 (+0.47%)
WDC : 343.43 (+1.64%)
SPY : 679.46 (-0.07%)
META : 629.86 (+0.23%)
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.

APLS : 40.79 (+0.34%)
BIIB : 172.97 (-2.34%)
Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , March 31, 2026 /PRNewswire/ -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

APLS : 40.79 (+0.34%)
Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

BIRD : 2.39 (-6.27%)
CNTA : 39.48 (-0.70%)
APLS : 40.79 (+0.34%)
Stocks Climb on Hopes for an End to Iran War

The S&P 500 Index ($SPX ) (SPY ) today is up +1.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.10%. June E-mini S&P futures (ESM26...

GOOGL : 317.24 (-0.39%)
AMAT : 399.49 (+0.42%)
AAPL : 260.48 (unch)
AVGO : 371.55 (+4.69%)
SNDK : 851.77 (+0.02%)
DHI : 142.64 (-0.77%)
BLDR : 85.30 (+0.11%)
CNTA : 39.48 (-0.70%)
$IUXX : 25,116.34 (+0.14%)
ASML : 1,478.28 (+2.05%)
ZNM26 : 111-030s (-0.13%)
MSFT : 370.87 (-0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 40.98
2nd Resistance Point 40.88
1st Resistance Point 40.84
Last Price 40.79
1st Support Level 40.70
2nd Support Level 40.60
3rd Support Level 40.56

See More

52-Week High 40.79
Last Price 40.79
Fibonacci 61.8% 31.36
Fibonacci 50% 28.44
Fibonacci 38.2% 25.53
52-Week Low 16.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.